Quince Therapeutics (QNCX) Competitors

Quince Therapeutics logo
$1.40 -0.02 (-1.41%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$1.40 0.00 (0.00%)
As of 02/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QNCX vs. URGN, FDMT, DSGN, CCCC, CRDF, ALMS, OGI, LFCR, CGEN, and LRMR

Should you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include UroGen Pharma (URGN), 4D Molecular Therapeutics (FDMT), Design Therapeutics (DSGN), C4 Therapeutics (CCCC), Cardiff Oncology (CRDF), Alumis (ALMS), Organigram (OGI), Lifecore Biomedical (LFCR), Compugen (CGEN), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.

Quince Therapeutics vs.

Quince Therapeutics (NASDAQ:QNCX) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Quince Therapeutics has higher earnings, but lower revenue than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quince TherapeuticsN/AN/A-$31.39M-$1.24-1.13
UroGen Pharma$82.71M3.05-$102.24M-$3.15-3.42

In the previous week, UroGen Pharma had 7 more articles in the media than Quince Therapeutics. MarketBeat recorded 7 mentions for UroGen Pharma and 0 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.00 beat UroGen Pharma's score of -0.09 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Quince Therapeutics Neutral
UroGen Pharma Neutral

UroGen Pharma received 361 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 74.04% of users gave UroGen Pharma an outperform vote.

CompanyUnderperformOutperform
Quince TherapeuticsOutperform Votes
7
100.00%
Underperform Votes
No Votes
UroGen PharmaOutperform Votes
368
74.04%
Underperform Votes
129
25.96%

Quince Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Quince Therapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 578.57%. UroGen Pharma has a consensus target price of $43.70, suggesting a potential upside of 305.76%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Quince Therapeutics is more favorable than UroGen Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quince Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.33
UroGen Pharma
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

Quince Therapeutics has a net margin of 0.00% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Quince Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Quince TherapeuticsN/A -53.27% -22.73%
UroGen Pharma -129.11%N/A -47.94%

Summary

Quince Therapeutics beats UroGen Pharma on 11 of the 18 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QNCX vs. The Competition

MetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$61.60M$3.09B$5.76B$9.22B
Dividend YieldN/A1.67%5.27%3.99%
P/E Ratio-1.1346.9826.1919.41
Price / SalesN/A316.26464.8976.77
Price / CashN/A192.7646.1438.90
Price / Book0.714.057.285.05
Net Income-$31.39M-$40.60M$3.19B$222.81M
7 Day Performance-2.10%3.50%1.68%1.29%
1 Month Performance-15.66%4.18%4.10%1.52%
1 Year Performance9.37%-10.55%22.06%16.53%

Quince Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QNCX
Quince Therapeutics
1.5434 of 5 stars
$1.40
-1.4%
$9.50
+578.6%
+9.4%$61.60MN/A-1.1360
URGN
UroGen Pharma
3.6907 of 5 stars
$10.73
+0.1%
$43.70
+307.3%
-44.3%$251.66M$89.36M-3.41200
FDMT
4D Molecular Therapeutics
3.2087 of 5 stars
$5.32
-10.9%
$33.25
+525.0%
-82.1%$245.94M$20.72M-1.87120Gap Up
DSGN
Design Therapeutics
1.9005 of 5 stars
$4.26
-0.7%
$7.00
+64.3%
+55.1%$241.20MN/A-5.0140Positive News
CCCC
C4 Therapeutics
2.894 of 5 stars
$3.37
-5.1%
$11.60
+244.2%
-60.2%$237.89M$20.76M-1.98150Short Interest ↓
News Coverage
CRDF
Cardiff Oncology
2.1203 of 5 stars
$4.58
+1.8%
$10.33
+125.6%
+148.0%$234.18M$490,000.00-4.8720Short Interest ↑
News Coverage
ALMS
Alumis
N/A$4.82
-15.0%
$26.57
+451.3%
N/A$227.60MN/A0.00N/A
OGI
Organigram
0.7296 of 5 stars
$1.73
+3.0%
N/A-41.7%$218.26M$117.47M-4.55860Earnings Report
Analyst Revision
LFCR
Lifecore Biomedical
2.2297 of 5 stars
$5.87
-0.7%
$8.00
+36.3%
-25.6%$217.37M$128.26M-10.48690
CGEN
Compugen
1.6018 of 5 stars
$2.42
-5.8%
$4.00
+65.3%
-7.5%$215.96M$33.46M121.0070
LRMR
Larimar Therapeutics
1.5339 of 5 stars
$3.37
-2.6%
$20.13
+497.2%
-73.9%$215.04MN/A-2.9330

Related Companies and Tools


This page (NASDAQ:QNCX) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners